FOXP1 is a potential biomarker of poor prognosis in patients with DLBCL (27, 28), Furthermore, the FOXP1-GINS1 axis is involved in DLBCL development and doxorubicin resistance (28). This evidence concerns the gene FOXP1 and diffuse large B-cell lymphoma.